Skip to main content

Table 5 Conditional logistic regression models to estimate the association between quintiles of PBDE and PBB-153 plasma levels expressed as ng/gr of lipids and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (N = 394)

From: Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort

ng/gr lipids in the plasma

Number (%)

controls

Number(%) cases

Model 0

OR [95% CI]

P trend

Model 1

OR [95% CI]

P trend

Model 2

OR [95% CI]

P trend

PBDE sum

197

197

      

 Q1

39(19.80)

44 (22.34)

Reference

0,85

Reference

0.82

Reference

0.74

  Q2

39(19.80)

29 (14.72)

0.68 [0.36–1.27]

 

0.56 [0.27–1.14]

 

0.63 [0.30–1.30]

 

 Q3

40(20.30)

39(19.80)

0.90 [0.51–1.59]

 

0.92 [0.49–1.71]

 

0.90 [0.48–1.70]

 

 Q4

39(19.80)

36(18.27)

0.82 [0.45–1.50]

 

0.77 [0.38–1.53]

 

0.85 [0.42–1.72]

 

 Q5

40(20.30)

49 (24.87)

1.10 [0.60–2.01]

 

0.96 [0.48–1.91]

 

1.01 [0.50–2.01]

 

log-PBDE sum

197

197

0.99 [0.68–1.45]

0.98

0.95 [0.62–1.46]

0.81

0.96 [0.62–1.49]

0.86

BDE-28

        

 Q1

39(19.80)

35 (17.77)

Reference

0.36

Reference

 

Reference

0.64

 Q2

39(19.80)

39(19.80)

1.09 [0.58–2.02]

 

1.56 [0.76–3.20]

0.55

1.48 [0.71–3.09]

 

 Q3

40(20.30)

33 (16.75)

0.91 [0.48–1.74]

 

0.87 [0.41–1.86]

 

0.91 [0.42–1.96]

 

 Q4

39(19.80)

43 (21.83)

1.19 [0.65–2.17]

 

1.22 [0.61–2.45]

 

1.34 [0.67–2.71]

 

 Q5

40(20.30)

47 (23.86)

1.27 [0.70–2.30]

 

1.28 [0.65–2.50]

 

1.19 [0.60–2.36]

 

log-BDE-28

  

1.05 [0.81–1.38]

0.7

0.99 [0.74–1.34]

0.9728

0.97 [0.71–1.33]

0.85

BDE-47

197

197

      

 Q1

39(19.80)

41 (20.81)

Reference

0.95

Reference

0.89

Reference

1,00

 Q2

39(19.80)

36(18.27)

0.89 [0.49–1.61]

 

0.76 [0.39–1.47]

 

0.73 [0.37–1.44]

 

 Q3

40(20.30)

37(18.78)

0.89 [0.49–1.62]

 

0.79 [0.40–1.53]

 

0.74 [0.37–1.46]

 

 Q4

39(19.80)

43 (21.83)

1.04 [0.59–1.86]

 

0.97 [0.50–1.88]

 

0.98 [0.50–1.93]

 

 Q5

40(20.30)

40(20.30)

0.95 [0.51–1.79]

 

0.89 [0.44–1.80]

 

0.93 [0.45–1.92]

 

log-BDE-47

  

0.95 [0.71–1.27]

0.71

0.92 [0.66–1.29]

0.6317

0.94 [0.66–1.32]

0.70

BDE-99

197

197

      

 Q1

39(19.80)

32 (16.24)

Reference

0.44

Reference

0.57

Reference

0.55

 Q2

39(19.80)

38(19.29)

1.23 [0.63–2.41]

 

1.20 [0.58–2.49]

 

1.25 [0.59–2.64]

 

 Q3

40(20.30)

40(20.30)

1.25 [0.64–2.44]

 

1.27 [0.61–2.64]

 

1.34 [0.64–2.84]

 

 Q4

39(19.80)

46 (23.35)

1.47 [0.76–2.83]

 

1.24 [0.60–2.58]

 

1.20 [0.57–2.52]

 

 Q5

40(20.30)

41 (20.81)

1.27 [0.66–2.44]

 

1.27 [0.61–2.67]

 

1.33 [0.63–2.81]

 

log-BDE-99

  

1.05 [0.79–1.41]

0.73

1.06 [0.76–1.47]

0.73

1.07 [0.76–1.49]

0.70

BDE-100

197

197

      

 Q1

39(19.80)

43 (21.83)

Reference

0.99

Reference

0.88

Reference

0.97

 Q2

39(19.80)

41 (20.81)

0.97 [0.53–1.81]

 

0.85 [0.42–1.69]

 

0.99 [0.48–2.01]

 

 Q3

40(20.30)

29 (14.72)

0.66 [0.35–1.27]

 

0.58 [0.27–1.24]

 

0.58 [0.27–1.25]

 

 Q4

39(19.80)

40(20.30)

0.94 [0.52–1.72]

 

0.96 [0.48–1.91]

 

0.96 [0.48–1.93]

 

 Q5

40(20.30)

44 (22.34)

1.01 [0.52–1.94]

 

0.87 [0.41–1.84]

 

0.99 [0.46–2.13]

 

log-BDE-100

  

0.90 [0.66–1.22]

0.48

0.86 [0.60–1.22]

0.40

0.87 [0.61–1.25]

0.46

BDE-153

197

197

      

 Q1

39(19.80)

48 (24.37)

Reference

0.85

Reference

0.84

Reference

0.87

 Q2

39(19.80)

34 (17.26)

0.68 [0.36–1.30]

 

0.60 [0.28–1.27]

 

0.62 [0.29–1.31]

 

 Q3

40(20.30)

29 (14.72)

0.57 [0.30–1.09]

 

0.52 [0.24–1.12]

 

0.53 [0.25–1.17]

 

 Q4

39(19.80)

36(18.27)

0.69 [0.35–1.34]

 

0.75 [0.34–1.63]

 

0.83 [0.37–1.85]

 

 Q5

40(20.30)

50 (25.38)

1.00 [0.56–1.80]

 

0.81 [0.41–1.61]

 

0.80 [0.40–1.61]

 

log-BDE-153

  

1.06 [0.64–1.76]

0.83

0.94 [0.52–1.68]

0.82

0.96 [0.53–1.73]

0.88

BDE-154

197

197

      

 Q1

39(19.80)

33 (16.75)

Reference

0.45

Reference

0.75

Reference

0.76

 Q2

39(19.80)

38(19.29)

1.18 [0.61–2.28]

 

0.91 [0.43–1.92]

 

0.86 [0.40–1.85]

 

 Q3

40(20.30)

41 (20.81)

1.26 [0.63–2.51]

 

1.30 [0.61–2.78]

 

1.35 [0.63–2.90]

 

 Q4

39(19.80)

46 (23.35)

1.48 [0.74–2.97]

 

1.37 [0.63–2.98]

 

1.26 [0.58–2.77]

 

 Q5

40(20.30)

39(19.80)

1.24 [0.63–2.44]

 

0.99 [0.46–2.11]

 

0.97 [0.45–2.10]

 

log-BDE-154

  

0.99 [0.75–1.32]

0.97

0.95 [0.69–1.31]

0.77

0.95 [0.69–1.32]

0.77

PBB-153

197

197

      

 Q1

39(19.80)

37(18.78)

Reference

0.59

Reference

0.80

Reference

0.74

 Q2

39(19.80)

44 (22.34)

1.21 [0.63–2.32]

 

1.25 [0.60–2.61]

 

1.19 [0.56–2.56]

 

 Q3

40(20.30)

41 (20.81)

1.12 [0.58–2.15]

 

1.09 [0.52–2.30]

 

1.05 [0.49–2.27]

 

 Q4

39(19.80)

53 (26.90)

1.41 [0.73–2.72]

 

1.74 [0.81–3.75]

 

1.83 [0.83–4.04]

 

 Q5

40(20.30)

22 (11.17)

0.62 [0.30–1.28]

 

0.61 [0.27–1.38]

 

0.52 [0.22–1.23]

 

log-PBB-153

  

1.06 [0.64–1.76]

0.83

0.94 [0.52–1.68]

0.83

0.96 [0.53–1.73]

0.88

  1. Model 0: crude estimates;
  2. Model 1: adjusted for smoking status (never vs. ever), physical activity measured in metabolic equivalent tasks (MET)-hour/week (< 35 vs. ≥35), education (≤ 12 years, 12 to 14 years, > 14 years), personal history of benign breast disease (no vs. yes), and family history of breast cancer (none, in first-degree relatives, in extended relatives), parity and age at first full-term pregnancy (FFTP) (no children, 1 or 2 children and < 30 years old at FFTP, ≥3 children and < 30 years old at FFTP, ≥ 30 years old at FFTP), total breastfeeding duration (never, ≤6 or > 6 months), age at menarche (< 13 years vs. ≥ 13 years), current use of menopausal hormone therapy (pre-menopausal, yes, no), and use of oral contraceptives (ever vs. never), menopausal status and age at menopause (pre-menopausal, menopause before age 51, menopause at age 51 or later);
  3. Model 2: Model 1 + adherence score to the Healthy and the Western dietary patterns (above vs. below the median)